208 related articles for article (PubMed ID: 28378918)
1. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
Schindler E; Amantea MA; Karlsson MO; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):373-382. PubMed ID: 28378918
[TBL] [Abstract][Full Text] [Related]
2. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
3. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
4. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
[TBL] [Abstract][Full Text] [Related]
5. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
[TBL] [Abstract][Full Text] [Related]
6. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
7. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
8. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
[TBL] [Abstract][Full Text] [Related]
9. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
10. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
[TBL] [Abstract][Full Text] [Related]
11. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
[TBL] [Abstract][Full Text] [Related]
12. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
13. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
14. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
15. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
Chen Y; Rini BI; Bair AH; Mugundu GM; Pithavala YK
Clin Pharmacokinet; 2015 Apr; 54(4):397-407. PubMed ID: 25343945
[TBL] [Abstract][Full Text] [Related]
17. Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib.
Mizuno R; Mikami S; Takamatsu K; Shinojima T; Kikuchi E; Oya M
Jpn J Clin Oncol; 2017 Dec; 47(12):1170-1174. PubMed ID: 28977627
[TBL] [Abstract][Full Text] [Related]
18. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
[TBL] [Abstract][Full Text] [Related]
19. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
20. Axitinib controlled metastatic renal cell carcinoma for 5 years.
Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]